Canrenone


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Hepatic diseases; HTN; Refractory oedema associated w/ heart failure 50-200 mg/day.
Dosage Details
Oral
Hepatic diseases, Hypertension, Refractory oedema associated with heart failure
Adult: 50-200 mg daily. Up to 300 mg daily may be required in some patients.
Contraindications
Hyperkalemia, hyponatremia, Addison's disease, severe renal impairment, pregnancy, lactation.
Special Precautions
Elderly, DM, renal or hepatic impairment, porphyria, patients likely to develop acidosis. Monitor serum electrolytes and blood-urea-nitrogen.
Adverse Reactions
Headache, drowsiness, GI disturbances, ataxia, mental confusion, skin rashes, gynecomastia, breast enlargement, hirsutism, deepening of the voice, menstrual irregularities, impotence, mild acidosis, lethargy, hyperkalaemia (discontinue), hyponatraemia, hepatotoxicity, osteomalacia, blood disorders.
Drug Interactions
Potassium supplements, other potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, trilostane. Lithium, thiazides, chlorpropamide, other antihypertensives, noradrenaline. Reduce ulcer-healing properties of carbenoxolone.
Lab Interference
Transient increases in blood-urea-nitrogen concentrations.
Action
Description: Canrenone acts on the distal portion of the renal tubule as a competitive antagonist of aldosterone. It increases sodium and water excretion and reduces potassium excretion.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Canrenone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in